Loading company…
Xellia Pharmaceuticals develops and manufactures anti-infective active pharmaceutical ingredients and finished dosage forms.
Founded in 1903 and headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals supplies fermentation-based non-beta-lactam anti-infectives to more than 500 pharmaceutical companies in over 80 countries. The company was acquired from Alpharma Inc. in February 2008 for USD 395 mn, and Carl-Åke Carlsson is CEO. In 2023 it reported revenue of USD 288.44 mn and EBITDA of -USD 160.64 mn. Its most recent funding was an LP Direct round totaling USD 700.00 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in